Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
British Journal of Cancer|November 20, 1998
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanomaM R Middleton, J M Lunn, C Morris, et al.
Targeted Oncology|May 13, 2016
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor OlaparibJ Mateo, V Moreno, A Gupta, et al.
British Journal of Cancer|March 6, 2008
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumoursS P Blagden, L R Molife, A Seebaran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2000
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanomaM R Middleton, J J Grob, N Aaronson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2009
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumoursD S Boss, G K Schwartz, M R Middleton, et al.
Scientific Reports|May 10, 2018
Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinomaT P MacGregor, R Carter, R S Gillies, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2021
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006G V Long, A Arance, L Mortier, et al.
ESMO Open|October 12, 2024
Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trialE Scanlon, A Lavery, M Albraikat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2018
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trialP G Corrie, A Marshall, P D Nathan, et al.
Pageof 6